Source apportionment and dynamics of PM across regions during and after the coronavirus 2019 pandemic.

Publication date: Jul 02, 2025

The coronavirus disease 2019 (COVID-19) pandemic was reported to improve air quality. However, the effects of lockdown on PM₂. ₅ and its chemical components based on source-specific characteristics remain unclear. This study evaluated and compared the components of PM₂. ₅ across three target sites-Seoul, Ansan-Siheung, and Wonju-based on source distribution patterns during the pandemic and post-pandemic periods. The results revealed that total ion concentrations decreased by 7-19% at the target sites, while trace element concentrations increased by 19-29% in the post-pandemic period. Carbon concentrations showed region-specific trends. Components associated with secondary formation, such as SO₄^2⁻, NO₃⁻, and NH₄⁺, decreased, whereas natural-origin components, such as Cl⁻, Na⁺, Mg^2⁺, and Ca^2⁺, increased, indicating enhanced dust resuspension. Furthermore, a positive matrix factorization (PMF) analysis demonstrated a predominance of primary emission sources and resuspended dust in the post-pandemic period, with a decline in contributions from secondary formation sources. These regional variations were primarily influenced by the extent of socioeconomic activities, with Seoul exhibiting a higher contribution from primary emissions and suspended dust. This study emphasizes the importance of establishing region-specific air quality improvement policies by scientifically identifying the impacts of anthropogenic activity on PM₂. ₅ components and their sources.

Open Access PDF

Concepts Keywords
Coronavirus Air Pollutants
Decline Air Pollutants
Scientifically Air Pollution
Seoul COVID-19
Socioeconomic COVID-19
Dust
Dust
Environmental Monitoring
Humans
Pandemics
Particulate Matter
Particulate Matter
PM2.5
Post-pandemic
Primary emission
Republic of Korea
SARS-CoV-2
Secondary formation

Semantics

Type Source Name
disease MESH coronavirus disease 2019
drug DRUGBANK Medical air
disease IDO quality
drug DRUGBANK Activated charcoal
disease MESH infection
drug DRUGBANK Coenzyme M
drug DRUGBANK Icosapent
disease IDO country
disease IDO host
disease IDO production
drug DRUGBANK Pidolic Acid
disease IDO process
disease MESH uncertainty

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *